Abstract Vascular endothelial growth factor (VEGF) plays a key role in the development of both proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DMO). In recent years, anti-VEGF agents have emerged as new approaches to the treatment of these devastating diabetic complications. Although Phase III studies in the diabetic population are needed, intravitreal anti-VEGF therapy is currently being used in clinical practice. Intravitreal injection is an effective means of delivering anti-VEGF drugs to the retina. However, this is an invasive procedure associated with potentially serious complications, such as endophthalmitis or retinal detachment, which may be significant for patients requiring serial treatment over many years. In addition, although delivered within the vitreous, anti-VEGF drugs could pass into the systemic circulation, which could potentially result in hypertension, proteinuria, increased cardiovascular events and impaired wound healing. Pegaptanib, ranibizumab and bevacizumab are the currently available anti-VEGF agents. Ranibizumab and bevacizumab block all VEGF isoforms, thus impairing both physiological and pathological neovascularisation. Pegaptanib only blocks the VEGF165 isoform, and would therefore seem the best option for avoiding systemic adverse effects in diabetic patients, although this remains to be demonstrated in clinical trials. In this regard, head-to-head studies designed to evaluate not only the efficacy, but also the systemic adverse effects of these drugs in a high-risk population such as diabetic patients are warranted.
diabetic retinopathy1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Diabetic_retinopathy  

clinical trials               1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Clinical_trial        

oedema                        1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Edema                 

vitreous                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Vitreous_humour       

VEGF                          1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Vascular_endothelial_growth_factor

ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

wound healing                 1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Wound_healing         

systemic circulation          0.9999999983753014^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Circulatory_system    

diabetic                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Diabetes_mellitus     

VEGF165                       1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Vascular_endothelial_growth_factor

Ranibizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Ranibizumab           

Vascular endothelial growth factor1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Vascular_endothelial_growth_factor

VEGF                          1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Vascular_endothelial_growth_factor

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

diabetic                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Diabetes_mellitus     

retina                        0.9999999999556621^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Retina                

diabetic                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Diabetes_mellitus     

cardiovascular                0.999941734659079^^http://www.w3.org/2001/XMLSchema#double            http://dbpedia.org/resource/Circulatory_system    

isoforms                      0.9999995464987597^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Protein_isoform       

diabetic                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Diabetes_mellitus     

intravitreal                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Intravitreal_administration

proteinuria                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Proteinuria           

bevacizumab                   1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Bevacizumab           

macular                       0.9999466199586057^^http://www.w3.org/2001/XMLSchema#double           http://dbpedia.org/resource/Macula_of_retina      

retinal detachment            1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Retinal_detachment    

endophthalmitis               1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Endophthalmitis       

hypertension                  1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Hypertension          

diabetic                      1.0^^http://www.w3.org/2001/XMLSchema#double                          http://dbpedia.org/resource/Diabetes_mellitus     

